Anna joined Sanofi-Genzyme in March of 2020 with over 30 years of diverse commercial experience which spans global market access, U.S. managed markets, marketing, product development and sales across the entire product life cycle of pharmaceutical and vaccine businesses.

Prior to joining Sanofii-Genzyme, Anna worked at Mallinckrodt Pharmaceuticals leading market access and pricing assessments in the Global New Products Market access group. Prior to Mallinckrodt, Anna worked 2.5 years at GSK, as the Global Market Access Franchise Partner leading the development of Market Access and pricing strategies for pre-commercial Oncology/Hematology assets resulting in R&D and commercial prioritization of IO, Epigenetic  and cell therapy assets.

Anna led the Global Market Access, Value and Pricing Strategies to drive coverage and reimbursement at BMS for Empliciti and Eliquis before departing to Kantar Health. In this latter role, Anna focused on commercial, global market access and US Managed Market strategies in Oncology and Hematology.

Anna spent 23 years at Merck where she held a number of positions with increasing responsibility which included negotiating US contracts with high control MCOs, leading US Marketing team for CV products and launching oncology supportive care product Emend.

Before starting her career at Merck, Anna was a Medical Technologist at Temple University Hospital and Safely Director at Pennsylvania Hospital both located in Philadelphia, PA.

Anna has a BS in Medical Technology from Rochester Institute of Technology and MBA in Healthcare Administration from Temple's Fox School of Business.